Skip to main content

Table 4 Absolute difference in adjusted cumulative incidence of diabetes (95% CI)

From: Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study

  6 months 12 months 18 months 24 months
DOACs vs Warfarin (ref.)
 Apixaban vs Warfarin − 0.79 (− 1.55 to 0.06) − 1.21 (− 2.44 to 0.09) − 1.66 (− 3.34 to 0.13) − 2.06 (-4.08 to 0.16)
 Dabigatran vs Warfarin − 1.17 (− 1.86 to − 0.41) − 1.80 (− 2.86 to − 0.65) − 2.47 (− 3.93 to − 0.92) − 3.06 (− 4.79 to − 1.15)
 Rivaroxaban vs Warfarin − 0.69 (− 1.42 to 0.09) − 1.06 (− 2.14 to 0.13) − 1.46 (− 2.93 to 0.19) − 1.80 (− 3.62 to 0.23)
 Apixaban/ Rivaroxaban vs Warfarin − 0.74 (− 1.39 to − 0.05) − 1.14 (− 2.10 to − 0.08) − 1.56 (− 2.83 to − 0.11) − 1.93 (− 3.62 to − 0.14)
DOACs vs DOACs (ref.)
 Apixaban vs Dabigatran 0.38 (− 0.38 to 1.13) 0.59 (− 0.59 to 1.69) 0.81 (− 0.79 to 2.34) 1.00 (− 0.97 to 2.86)
 Rivaroxaban vs Dabigatran 0.48 (− 0.20 to 1.11) 0.74 (− 0.31 to 1.73) 1.01 (− 0.43 to 2.31) 1.26 (− 0.52 to 2.86)
 Rivaroxaban vs Apixaban 0.10 (− 0.73 to 0.85) 0.15 (− 1.07 to 1.34) 0.21 (− 1.49 to 1.85) 0.26 (− 1.81 to 2.30)
 Apixaban/ Rivaroxaban vs Dabigatran 0.43 (− 0.14 to 0.93) 0.66 (− 0.22 to 1.42) 0.91 (− 0.31 to 2.00) 1.13 (− 0.38 to 2.47)
  1. 95% confidence interval was estimated using bootstrap methods